Sidley advised on the initial public offering (IPO) and H share listing of TransThera Sciences (Nanjing), Inc. (HKEX: 2617, TransThera) on the Main Board of the Hong Kong Stock Exchange (HKEX) under Chapter 18A of the Hong Kong Listing Rules. Sidley acted as Hong Kong and U.S. counsel for joint sponsors CITIC Securities (Hong Kong) Limited and Huatai Financial Holdings (Hong Kong) Limited, and the underwriters.
Founded in 2014, TransThera is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.
The Sidley team was led by partners Meng Ding and Claudia Yu. Other team members included counsel Liming Xu, senior managing associate William Lau, managing associate Yiming Chen, China Advisor Alice Liu, and legal assistant Andy Tam.
Since the launch of the Chapter 18A listing regime in April 2018, Sidley has been a pioneer in advising biotech IPOs in Hong Kong. Notably, it is the only Band One firm ranked by Chambers Greater China Region/APAC in life sciences for 16 consecutive years. Sidley has been “highly recommended” in “Innovative Lawyers in Unlock Capital” by the FT Innovative Lawyers APAC Awards in May this year, recognizing its contribution in “Reformed Listing Rules on the HKEX - revitalizing the Hong Kong IPO market.” Its Capital Markets practice has also received a number of independent recognitions from publications such as The Asia Legal Awards by Law.com International, IFLR APAC Awards, China Business Law Journal and Legal 500 APAC.
